세계의 노인황반변성(AMD) 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Age Related Macular Degeneration (AMD) Therapeutics Market is poised to witness substantial growth, reaching a value of USD 27.72 Billion by the year 2033, up from USD 14.49 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 7.48% between 2025 and 2033.

The age-related macular degeneration (AMD) therapeutics market is advancing rapidly, driven by the increasing prevalence of AMD due to aging populations and the growing focus on preserving vision and quality of life. Therapeutic innovations encompass anti-VEGF agents, gene therapies, and novel drug delivery systems targeting the underlying pathophysiology of both dry and wet AMD forms. Advances in molecular biology and biomarker identification are enabling personalized treatment approaches and earlier intervention. Sustained-release implants and minimally invasive administration techniques are improving patient compliance and treatment outcomes.

The integration of diagnostic imaging technologies, such as optical coherence tomography (OCT), with therapeutic monitoring is enhancing disease management precision. Research into regenerative medicine and stem cell therapies holds promise for restoring retinal function. Regulatory approvals and reimbursement policies are facilitating market access and adoption. Additionally, increasing awareness and screening programs are driving early diagnosis and treatment initiation.

Collaborations among pharmaceutical companies, research institutions, and healthcare providers are accelerating clinical trials and product development. As AMD remains a leading cause of vision loss globally, the therapeutics market is poised for significant growth, delivering innovative solutions that address unmet medical needs and improve patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Age Related Macular Degeneration (AMD) Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other Products

By Disease Type

• Wet AMD
• Dry AMD

By Age Group

• 50-64 Years
• 65-74 Years
• 75 and Above

By Distribution Channel

• Hospital Pharmacies
• Specialty and Retail Pharmacies
• E-Commerce
• List of Companies Profiled in the report
• Amgen Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biocon Biologics Ltd., Biogen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group AG, STADA Arzneimittel AG, Xbrane Biopharma AB

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Disease Type
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Eylea Historic and Forecast Sales By Regions
• 5.4. Lucentis Historic and Forecast Sales By Regions
• 5.5. Beovu Historic and Forecast Sales By Regions
• 5.6. Vabysmo Historic and Forecast Sales By Regions
• 5.7. Syfovre Historic and Forecast Sales By Regions
• 5.8. Avastin Historic and Forecast Sales By Regions
• 5.9. Other Products Historic and Forecast Sales By Regions

6. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

• 6.1. Overview By Disease Type
• 6.2. Historical and Forecast Data Analysis By Disease Type
• 6.3. Wet AMD Historic and Forecast Sales By Regions
• 6.4. Dry AMD Historic and Forecast Sales By Regions

7. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data Analysis By Age Group
• 7.3. 50-64 Years Historic and Forecast Sales By Regions
• 7.4. 65-74 Years Historic and Forecast Sales By Regions
• 7.5. 75 and Above Historic and Forecast Sales By Regions

8. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 8.4. Specialty and Retail Pharmacies Historic and Forecast Sales By Regions
• 8.5. E-Commerce Historic and Forecast Sales By Regions

9. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS COMPANIES

• 10.1. Age Related Macular Degeneration (AMD) Therapeutics Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Amgen Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Apellis Pharmaceuticals Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Bayer AG
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Biocon Biologics Ltd.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Biogen Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Celltrion Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. F. Hoffmann-La Roche Ltd
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Formycon AG
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Novartis AG
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Pfizer Inc.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Regeneron Pharmaceuticals Inc.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. Sandoz Group AG
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. STADA Arzneimittel AG
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Xbrane Biopharma AB
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies